Table 1 Characteristics of included studies
|  | Aetiology | Number of patients with HIV and VPS | Mean age (years) (SD)a | Mean CD4 count (cells/μL; ±SD)a | Included outcome | Follow-upb | Number of non-HIV infected controls (mean age [±SD]) | Country |
|---|---|---|---|---|---|---|---|---|
Bach 1997 [45] | CM | 4 | 39.25 (±6.1) | 28.75(±14.4) | Survival | 3d-12y | N/A | USA |
Calvo 2003 [75] | CM | 5 | 28.2 (±7.7) | unknown | Survival | 6 m | N/A | Uruguay |
Cherian 2016 [74] | CM | 8 | 38.9 (±8.2) | Unknown | Survival | 6 m-5.7y | N/A | USA |
Corti 2014 [73] | CM | 14 | 33 (18–53)* | 50 (6–511)* | Survival | 1y | N/A | Argentina |
Liu 2014 [72] | CM | 9 | 32.2(±6.0) | 10.75(±9.4) | Survival | 1 m-1y | N/A | China |
Vidal 2012 [53] | CM | 9 | Unknown | Unknown | Survival | Discharge | N/A | Brazil |
Nadvi 2000 [46] | TBM | 15 | 26.1 (±16.4) | 171.7(±161.5) | GOS | 1 m | 15 patients (age 10.7[±9.6]) | South Africa |
Sharma 2015 [44] | TBM | 30 | 31.3(±7.8) | 143 (26–445)** | GOS | 3 m | 30 patients (age 31[±9.9]) | India |
Harrichandparsad 2019 [79] | TBM | 30 | 28.4(±13.4) | 227(±163.9) | GOS | 1 m | N/A | South Africa |